Extensive Clinical Experience
NanoPass MicronJet Technology has already been used to administer over 26,000 injections to approximately 4,900 patients in more than 45 clinical trials, some still ongoing. The studies, conducted on subjects ranging in age from 6-week-old infants to 95 years in North America, Europe, Israel, Hong Kong, Brazil, Bangladesh and Japan, represent one of the industry’s most comprehensive database on intradermal delivery.
MicronJet600 has demonstrated a superior immune response to full-dose Fluzone® intramuscular5 and improved immunogenicity to full-dose ZostaVax® and overall trend for superiority with lower doses8.
Micronjet600 has demonstrated significant dose sparing with various vaccines with 4-40% of the dose1-8,10. It is also the first ID device to demonstrate dose sparing in pandemic flu4.